Traders should monitor the pricing and conversion terms of the notes. The offering could pressure the stock in the near term due to dilution concerns, but if proceeds are used for a transformative catalyst (e.g., late-stage trial results), the long-term outlook may improve. Watch for the final prospectus and any updates on use of proceeds.
CELC drugs
CELC drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $88.95entry
- T+1 · 6mo ago +3.96%α +3.56% · $92.47
- T+5 · 5mo ago −0.80%α +3.02% · $88.24
- T+20 · 5mo ago +21.36%α +22.36% · $107.95
- T+60 · 3mo ago +4.82%α +2.32% · $93.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity announced a proposed $400M underwritten public offering of convertible senior notes due 2032. The offering is dilutive to existing shareholders and signals significant capital needs for a clinical-stage biotech, likely to fund pipeline development. Given the company's pre-revenue status and the large size relative to its $4.5B market cap, this is a notable but not transformative event.
Key Financial Metrics
Key Facts
- Proposed underwritten public offering of $400M aggregate principal amount of convertible senior notes due 2032.
- Celcuity is a clinical-stage biotechnology company with no approved products or disclosed revenue.
- The offering represents approximately 8.9% of the company's $4.5B market cap.
- Convertible notes will likely convert into equity, adding dilution over time.
Financial Impact
$400M convertible note offering, representing ~8.9% of market cap
Risk Factors
- Dilution from conversion of notes could exceed 8.9% if stock price appreciates.
- Clinical-stage biotech risk: no revenue, pipeline failure could render debt burdensome.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305935 |
Track record
26 reports on CELC
6 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers